Women's Health Initiative
Long-term U.S. health study
Follow Women's Health Initiative on Notably News to receive short updates to your email — rarely!
| 2022 | USPSTF again evaluated HRT and maintained their 'D' score recommendation against using hormone replacement therapy for chronic disease prevention in postmenopausal women. |
| 2022 | The USPSTF reaffirmed their 2017 recommendation against using hormone replacement therapy for chronic disease prevention in postmenopausal women, maintaining a 'D' grade assessment. |
| 2022 | The United States Preventive Services Task Force reaffirmed its 'D' score recommendation against hormone replacement therapy for chronic disease prevention in postmenopausal women. |
| 2022 | The United States Preventive Services Task Force reaffirmed their 'D' score recommendation against hormone replacement therapy for chronic postmenopausal symptom treatment. |
| 2020 | American Psychological Association (APA) published data revealing critical disparities in mental health provider demographics: less than 5% of mental healthcare providers were Black, 4% were Asian American, 4% were Hispanic, and only 2% of psychiatrists were Black. |
| 2020 | Analysis showed a persistent reduction in all-cause and breast cancer-specific mortality for women following a low-fat dietary intervention, with 19.6 years of cumulative follow-up demonstrating continued health benefits. |
| July 28 2020 | Most recent study update published in JAMA, reporting persistent increased breast cancer risk among women randomized to estrogen plus progestin compared with placebo, with a hazard ratio of 1.28. |
| July 28 2020 | JAMA publication updated findings on breast cancer risk, reporting persistent increased risk for women randomized to estrogen plus progestin (hazard ratio 1.28, with statistical significance P-value < 0.001). |
| July 28 2020 | JAMA publication revealed significantly lower breast cancer risk for the estrogen-alone group compared to placebo, with reduced breast cancer incidence and mortality. |
| 2019 | Pregnancy statistics revealed that 16% of pregnancies experienced hypertensive disorders, highlighting significant reproductive health challenges for women in the United States. |
| 2019 | A quantitative study by Penn University revealed that women with a history of infertility have a 20% increased risk of cancer-related mortality, including higher risks of breast cancer and diabetes-related deaths. |
| 2017 | Women of color reported significantly higher rates of mental health challenges, including feelings of worthlessness, hopelessness, and sadness, almost twice as often as white women. |
| 2017 | Cumulative 18-year follow-up analysis published, examining 27,347 postmenopausal women who participated in the original WHI hormone therapy trials, finding no significant association between hormone interventions and mortality risks. |
| 2017 | The United States Preventive Services Task Force downgraded hormone replacement therapy recommendations to a 'D' score, discouraging its use for prevention of chronic diseases in postmenopausal women. |
| April 2016 | The American Association for Cancer Research (AACR) awarded the WHI study the Team Science Award, acknowledging its over 20 years of work that fundamentally transformed women's medicine globally. |
| 2015 | ART success rates were documented across different age groups, showing 31% success for women younger than 35, 16% for women aged 38-40, and 3% for women over 44 years old. |
| 2015 | 1.7% of all live births in the United States were the result of Assisted Reproductive Technology (ART), highlighting the growing prevalence of this fertility treatment method. |
| 2015 | The Women's Health Initiative (WHI) study was awarded the Team Science Award from the Association for Clinical and Translational Science (ACTS), recognizing the study's success in translating research discoveries into clinical applications and widespread clinical practice. |
| 2015 | The Women's Health Initiative launched the WHISH (Strong and Healthy) Study to examine the impact of physical activity on older women's health, enrolling nearly 50,000 participants to investigate outcomes related to heart disease and independent lifestyle maintenance. |
| 2015 | Extension Study 3 begins, with preliminary estimates showing 81,386 participants (87% of those previously enrolled in Extension Study 2) remain active, including 36,115 Clinical Trial participants and 45,271 Observational Study participants. |
| 2014 | An economic analysis calculated a net economic return of $37.1 billion for the estrogen-plus-progestin arm of the hormone trial, demonstrating the significant value of the large-scale population study. |
| 2013 | Approximately 7,400 Long Life Study participants were enrolled in the Objective Physical Activity and Cardiovascular Health in Women (OPACH) study to assess physical activity and its correlation with cardiovascular disease and mortality. |
| 2013 | A comprehensive analysis of extramural clinical trials by NHLBI highlighted the Women's Health Initiative (WHI) as having exceptionally cited research, with the Estrogen + Progestin (E+P) trial ranking first among all NHLBI-sponsored clinical trials, averaging 812.5 citations annually. |
| May 2013 | The Long Life Study (LLS) completed its in-person visits and blood collections, involving 7,875 participants aged 63-99 from the Extension Study 2, aimed at establishing new baselines for studies on disease and aging. |
| 2010 | Extension Study 2 is initiated, enrolling 93,540 participants (87% of those eligible from Extension Study 1). |
This contents of the box above is based on material from the Wikipedia articles Women's reproductive health in the United States & Women's Health Initiative, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.